News items Meniscus prosthesis Atro Medical receives 2.5 million EU grant

10 June 2022

The European Commission is providing a 2.5 million euro grant to ATRO Medical, spin-off of The Radboudumc and DSM, for the accelerated development of their artificial meniscus. The Dutch startup is working on the first anatomical meniscus prostheses for patients with chronic knee pain.
The EIC Accelerator program is the European Commission's main instrument for supporting promising healthcare innovations. The program aims to develop and scale up breakthrough innovations. The EIC Accelerator Grant also provides access to an investment from the EIC Fund, coordinated by the European Commission and used in particular to bridge the funding gap between market entry and scale-up.


The €2.5 million grant will be spent on accelerating preclinical testing of the meniscus prostheses, health economic analyses and international clinical studies. All efforts combined will accelerate the implementation of this Dutch healthcare innovation. ATRO Medical is the first company in the world to have solutions for both inner and outer meniscus near the clinical stage. 

Thousands of patients with chronic knee pain are waiting for these solutions. Their meniscus has been removed due to previous trauma and they have developed what is known as post-meniscectomy pain syndrome. Orthopedic surgeon and Chief Medical Officer Dr. Tony van Tienen explains: "In my clinical practice I see many patients with chronic knee pain. Most of them are too young for a total knee replacement. However, they want to be able to go to work, store or just walk their dog without being constantly bothered by a painful knee. Our artificial meniscus is designed to relieve that pain. Pain-free mobility, that's what we're aiming for."

Clinical Evidence

ATRO Medical has already received several international recognitions for their work, including the breakthrough device designation from the US FDA, Eurostars funding and an innovation award from Johnson & Johnson. Thanks in part to these awards, the company can focus on expanding clinical evidence in the coming years, which will allow the necessary market registration to be realized. Atro Medical works with partners such as ReumaNederland, the Orthopaedic Research Laboratory of the Radboudumc and international clinics such as the Sint Maartenskliniek, Mayo Clinic and Sporthopaedicum Berlin. 


Related news items

More accurate surgery with the Anatomy Projector

30 May 2022

The Anatomy Projector, developed at the Radboudumc, allows surgeons to operate much more accurately with projected augmented reality.

read more

Field research on malaria vaccine offers unexpected surprise

23 May 2022

Field research on the effectiveness of a malaria vaccine, came up with unexpected results for an international group of researchers including Benjamin Mordmüller of Radboudumc. The vaccine evokes a broader response against malaria proteins than there are in the vaccine.

read more

Rubicon grants awarded to three RIMLS researchers

19 April 2022 Three researchers have received Rubicon funding from NWO/ZonMw. This will enable Elke Muntjewerff, Laura de Vries and Laurens van de Wiel to do research at a foreign research institute for the next two years. read more

Tailored drug dosage for pregnant women

14 March 2022 Three quarters of women in the Netherlands use some form of medication during pregnancy, but little is known about the appropriate dosages. Research by the Radboudumc, MUMC+ and Lareb Mothers of Tomorrow should change this. read more

NIH grant for follow-up research on tuberculous meningitis

10 February 2022 Met subsidie van het Amerikaanse NIH gaat With a grant from the U.S. NIH, Reinout van Crevel will continue to unravel the disease process of tuberculous meningitis. read more

Survey of patients to address knee pain from removed meniscus

19 November 2021 Patients with persistent knee pain after meniscus removal can participate at three locations in the Netherlands in the AIR2 study by ATRO Medical, a spin-off of the Radboudumc and DSM. read more